메뉴 건너뛰기




Volumn 9, Issue , 2011, Pages

A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients

Author keywords

Assessment methods; Non serious adverse drug events; Observational studies; Type 2 diabetes mellitus

Indexed keywords

ORAL ANTIDIABETIC AGENT; DRUG;

EID: 80053175593     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-9-83     Document Type: Review
Times cited : (18)

References (101)
  • 2
    • 22744434641 scopus 로고    scopus 로고
    • European Haemophilia Therapy Standardisation Board. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders
    • 10.1111/j.1365-2516.2005.01114.x, 16011587
    • Lassila R, Rothschild C, De Moerloose P, Richards M, Perez R, Gajek H. European Haemophilia Therapy Standardisation Board. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 2005, 11:353-359. 10.1111/j.1365-2516.2005.01114.x, 16011587.
    • (2005) Haemophilia , vol.11 , pp. 353-359
    • Lassila, R.1    Rothschild, C.2    De Moerloose, P.3    Richards, M.4    Perez, R.5    Gajek, H.6
  • 3
    • 33646744337 scopus 로고    scopus 로고
    • Under-reporting of adverse drug reactions: a systematic review
    • 10.2165/00002018-200629050-00003, 16689555
    • Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006, 29:385-396. 10.2165/00002018-200629050-00003, 16689555.
    • (2006) Drug Saf , vol.29 , pp. 385-396
    • Hazell, L.1    Shakir, S.A.W.2
  • 4
    • 77949407113 scopus 로고    scopus 로고
    • The missing voice of patients in drug-safety reporting
    • 10.1056/NEJMp0911494, 3031980, 20220181
    • Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010, 362:865-869. 10.1056/NEJMp0911494, 3031980, 20220181.
    • (2010) N Engl J Med , vol.362 , pp. 865-869
    • Basch, E.1
  • 6
    • 37749024537 scopus 로고    scopus 로고
    • Importance of observational studies in clinical practice
    • Spec No, 10.1016/j.clinthera.2007.07.004, 18046928
    • Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007, 29:1284-1292. Spec No, 10.1016/j.clinthera.2007.07.004, 18046928.
    • (2007) Clin Ther , vol.29 , pp. 1284-1292
    • Ligthelm, R.J.1    Borzì, V.2    Gumprecht, J.3    Kawamori, R.4    Wenying, Y.5    Valensi, P.6
  • 7
    • 0031696868 scopus 로고    scopus 로고
    • Prescription-event monitoring--recent progress and future horizons
    • 1873686, 9764958
    • Mann RD. Prescription-event monitoring--recent progress and future horizons. Br J Clin Pharmacol 1998, 46:195-201. 1873686, 9764958.
    • (1998) Br J Clin Pharmacol , vol.46 , pp. 195-201
    • Mann, R.D.1
  • 8
    • 33644906137 scopus 로고    scopus 로고
    • Brief communication: Better ways to question patients about adverse medical events: A Randomized, Controlled Trial
    • Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: A Randomized, Controlled Trial. Ann Intern Med 2006, 144:257-261.
    • (2006) Ann Intern Med , vol.144 , pp. 257-261
    • Bent, S.1    Padula, A.2    Avins, A.L.3
  • 10
    • 80054916474 scopus 로고    scopus 로고
    • ICH Topic E 2 E Pharmacovigilance Planning (Pvp) Note for guidance on planning pharmacovigilance activities (CPMP/ICH/5716/03) [online]
    • European Medicines Agency Committee for medicinal products for human use (CHMP)
    • European Medicines Agency Committee for medicinal products for human use (CHMP) ICH Topic E 2 E Pharmacovigilance Planning (Pvp) Note for guidance on planning pharmacovigilance activities (CPMP/ICH/5716/03) [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ich/571603en.pdf
    • (2011)
  • 11
    • 80054911814 scopus 로고    scopus 로고
    • ICH Topic E1 The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions (CPMP/ICH/375/95) [online]
    • European Medicines Agency Committee for medicinal products for human use (CHMP)
    • European Medicines Agency Committee for medicinal products for human use (CHMP) ICH Topic E1 The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions (CPMP/ICH/375/95) [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ich/037595en.pdf
    • (2011)
  • 12
    • 80054922388 scopus 로고    scopus 로고
    • Guidance for Industry. Premarketing Risk Assessment, March 2005 [online]
    • US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)
    • US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for Industry. Premarketing Risk Assessment, March 2005 [online]. 2011, US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)., http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126958.pdf
    • (2011)
  • 13
    • 77954655813 scopus 로고    scopus 로고
    • ICH Topic E6 (R1) Guideline for Good Clinical Practice (CPMP/ICH/135/95) [online]
    • European Medicines Agency Committee for medicinal products for human use (CHMP)
    • European Medicines Agency Committee for medicinal products for human use (CHMP) ICH Topic E6 (R1) Guideline for Good Clinical Practice (CPMP/ICH/135/95) [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf
    • (2011)
  • 14
    • 4043084862 scopus 로고    scopus 로고
    • Adverse drug events and medication errors: detection and classification methods
    • 10.1136/qshc.2004.010611, 1743868, 15289635
    • Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004, 13:306-314. 10.1136/qshc.2004.010611, 1743868, 15289635.
    • (2004) Qual Saf Health Care , vol.13 , pp. 306-314
    • Morimoto, T.1    Gandhi, T.K.2    Seger, A.C.3    Hsieh, T.C.4    Bates, D.W.5
  • 15
    • 12344312699 scopus 로고    scopus 로고
    • Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0, August 9, 2006 [online]
    • National Cancer Institute. Cancer Therapy Evaluation Program
    • National Cancer Institute. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0, August 9, 2006 [online]. 2011, National Cancer Institute. Cancer Therapy Evaluation Program., http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
    • (2011)
  • 16
    • 80054883512 scopus 로고    scopus 로고
    • Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes December, 2008 [online]
    • US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)
    • US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes December, 2008 [online]. 2011, US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
    • (2011)
  • 17
    • 80054908200 scopus 로고    scopus 로고
    • Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. Draft. CPMP/EWP/1080/00 Rev. 1. 20 Jan 2010 [online]
    • European Medicines Agency Committee for medicinal products for human use (CHMP)
    • European Medicines Agency Committee for medicinal products for human use (CHMP) Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. Draft. CPMP/EWP/1080/00 Rev. 1. 20 Jan 2010 [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ewp/108000enrev1.pdf
    • (2011)
  • 18
    • 0035186582 scopus 로고    scopus 로고
    • Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
    • 10.1046/j.1365-2036.2001.00896.x, 11136287
    • Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther 2001, 15:137-142. 10.1046/j.1365-2036.2001.00896.x, 11136287.
    • (2001) Aliment Pharmacol Ther , vol.15 , pp. 137-142
    • Bytzer, P.1    Talley, N.J.2    Jones, M.P.3    Horowitz, M.4
  • 19
    • 35648987622 scopus 로고    scopus 로고
    • Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes
    • 10.1016/j.diabres.2005.07.013, 17517445
    • Woodcock A, Bain S, Charlton M, Bradley C. Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes. Diabetes Res Clin Pract 2007, 78:324-333. 10.1016/j.diabres.2005.07.013, 17517445.
    • (2007) Diabetes Res Clin Pract , vol.78 , pp. 324-333
    • Woodcock, A.1    Bain, S.2    Charlton, M.3    Bradley, C.4
  • 20
    • 43449094999 scopus 로고    scopus 로고
    • Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France
    • Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008, 10(suppl 1):16-24.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.SUPPL. 1 , pp. 16-24
    • Vexiau, P.1    Mavros, P.2    Krishnarajah, G.3    Lyu, R.4    Yin, D.5
  • 21
    • 33750573488 scopus 로고    scopus 로고
    • Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma - interviewing patients at home
    • 10.1007/s11096-006-9023-9, 17066246
    • Haugbolle LS, Sorensen EW. Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma - interviewing patients at home. Pharm World Sci 2006, 28:239-247. 10.1007/s11096-006-9023-9, 17066246.
    • (2006) Pharm World Sci , vol.28 , pp. 239-247
    • Haugbolle, L.S.1    Sorensen, E.W.2
  • 22
    • 56549084177 scopus 로고    scopus 로고
    • Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria
    • 10.1007/s11096-008-9243-2, 18784982
    • Yusuff KB, Obe O, Joseph BY. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharm World Sci 2008, 30:876-883. 10.1007/s11096-008-9243-2, 18784982.
    • (2008) Pharm World Sci , vol.30 , pp. 876-883
    • Yusuff, K.B.1    Obe, O.2    Joseph, B.Y.3
  • 23
    • 0142105928 scopus 로고    scopus 로고
    • Effect of add-on acarbose to insulin therapy in routine clinical practice
    • Klocke KR, Stauch K, Landen H. Effect of add-on acarbose to insulin therapy in routine clinical practice. Clin Drug Invest 2003, 23:621-627.
    • (2003) Clin Drug Invest , vol.23 , pp. 621-627
    • Klocke, K.R.1    Stauch, K.2    Landen, H.3
  • 25
    • 0033366695 scopus 로고    scopus 로고
    • Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
    • 10.2337/diacare.22.12.2067, 10587844
    • Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999, 22:2067-2071. 10.2337/diacare.22.12.2067, 10587844.
    • (1999) Diabetes Care , vol.22 , pp. 2067-2071
    • Jick, S.S.1    Stender, M.2    Myers, M.W.3
  • 26
    • 34247871323 scopus 로고    scopus 로고
    • Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration
    • UK Hypoglycaemia Study Group
    • UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147. UK Hypoglycaemia Study Group.
    • (2007) Diabetologia , vol.50 , pp. 1140-1147
  • 27
    • 33645029685 scopus 로고    scopus 로고
    • Postmarketing study of nateglinide in Japan: treatment of medication-naive patients with type 2 diabetes
    • 10.1007/BF02849956, 16510379
    • Taki H, Maki T, Iso T, Tanabe S, Kajiura T. Postmarketing study of nateglinide in Japan: treatment of medication-naive patients with type 2 diabetes. Adv Ther 2005, 22:621-635. 10.1007/BF02849956, 16510379.
    • (2005) Adv Ther , vol.22 , pp. 621-635
    • Taki, H.1    Maki, T.2    Iso, T.3    Tanabe, S.4    Kajiura, T.5
  • 28
    • 31144458077 scopus 로고    scopus 로고
    • Postmarketing surveillance study of nateglinide in Japan
    • 10.1007/BF02849871, 16418160
    • Taki H, Maki T, Iso T, Iwamoto K, Kajiura T. Postmarketing surveillance study of nateglinide in Japan. Adv Ther 2005, 22:513-526. 10.1007/BF02849871, 16418160.
    • (2005) Adv Ther , vol.22 , pp. 513-526
    • Taki, H.1    Maki, T.2    Iso, T.3    Iwamoto, K.4    Kajiura, T.5
  • 29
    • 0035115289 scopus 로고    scopus 로고
    • Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting
    • 10.2165/00002018-200124020-00004, 11235818
    • Biswas P, Wilton LV, Shakir SAW. Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting. Drug Saf 2001, 24:149-154. 10.2165/00002018-200124020-00004, 11235818.
    • (2001) Drug Saf , vol.24 , pp. 149-154
    • Biswas, P.1    Wilton, L.V.2    Shakir, S.A.W.3
  • 30
    • 0033799522 scopus 로고    scopus 로고
    • Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes
    • Landgraf R, Frank M, Bauer C, Dieken ML. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. Int J Obes Relat Metab Disord 2000, 24(suppl 3):S38-44.
    • (2000) Int J Obes Relat Metab Disord , vol.24 , Issue.SUPPL. 3
    • Landgraf, R.1    Frank, M.2    Bauer, C.3    Dieken, M.L.4
  • 31
    • 33947168360 scopus 로고    scopus 로고
    • Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus
    • 10.1016/j.clinthera.2007.01.014, 17379058
    • Chao J, Nau DP, Aikens JE. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. Clin Ther 2007, 29:177-180. 10.1016/j.clinthera.2007.01.014, 17379058.
    • (2007) Clin Ther , vol.29 , pp. 177-180
    • Chao, J.1    Nau, D.P.2    Aikens, J.E.3
  • 32
    • 43549097824 scopus 로고    scopus 로고
    • The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions
    • 10.1089/dia.2008.0244, 18473695
    • Karagiannis E, Pfutzner A, Forst T, Lubben G, Roth W, Grabellus M, Flannery M, Schondorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008, 10:206-212. 10.1089/dia.2008.0244, 18473695.
    • (2008) Diabetes Technol Ther , vol.10 , pp. 206-212
    • Karagiannis, E.1    Pfutzner, A.2    Forst, T.3    Lubben, G.4    Roth, W.5    Grabellus, M.6    Flannery, M.7    Schondorf, T.8
  • 33
    • 46149094137 scopus 로고    scopus 로고
    • The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy
    • 10.1016/j.ejheart.2008.05.013, 18571471
    • McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008, 10:703-708. 10.1016/j.ejheart.2008.05.013, 18571471.
    • (2008) Eur J Heart Fail , vol.10 , pp. 703-708
    • McAlister, F.A.1    Eurich, D.T.2    Majumdar, S.R.3    Johnson, J.A.4
  • 34
    • 46149094865 scopus 로고    scopus 로고
    • Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes
    • 10.1007/s12020-008-9042-5, 18266113
    • Chokrungvaranon N, Chentanez T, Arakaki RF. Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. Endocrine 2007, 32:311-316. 10.1007/s12020-008-9042-5, 18266113.
    • (2007) Endocrine , vol.32 , pp. 311-316
    • Chokrungvaranon, N.1    Chentanez, T.2    Arakaki, R.F.3
  • 35
    • 46349089552 scopus 로고    scopus 로고
    • Evaluation of adverse events of oral antihyperglycaemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis
    • 10.2165/00002512-200825070-00006, 18582148
    • Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Evaluation of adverse events of oral antihyperglycaemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging 2008, 25:611-622. 10.2165/00002512-200825070-00006, 18582148.
    • (2008) Drugs Aging , vol.25 , pp. 611-622
    • Asche, C.V.1    McAdam-Marx, C.2    Shane-McWhorter, L.3    Sheng, X.4    Plauschinat, C.A.5
  • 36
    • 33745700035 scopus 로고    scopus 로고
    • Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
    • 10.1185/030079906X112598, 16846554
    • Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin 2006, 22:1211-1215. 10.1185/030079906X112598, 16846554.
    • (2006) Curr Med Res Opin , vol.22 , pp. 1211-1215
    • Hanefeld, M.1    Pfutzner, A.2    Forst, T.3    Lubben, G.4
  • 37
    • 0041333132 scopus 로고    scopus 로고
    • Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels
    • Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 2003, 25(suppl B):B64-B80.
    • (2003) Clin Ther , vol.25 B , Issue.SUPPL
    • Olansky, L.1    Marchetti, A.2    Lau, H.3
  • 38
    • 1942438519 scopus 로고    scopus 로고
    • Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
    • 10.1185/030079904125003278, 15119994
    • Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004, 20:565-572. 10.1185/030079904125003278, 15119994.
    • (2004) Curr Med Res Opin , vol.20 , pp. 565-572
    • Blonde, L.1    Dailey, G.E.2    Jabbour, S.A.3    Reasner, C.A.4    Mills, D.J.5
  • 39
    • 11344289613 scopus 로고    scopus 로고
    • Vitamin B12 status of patients treated with metformin: A cross-sectional cohort study
    • Hermann LS, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: A cross-sectional cohort study. Br J Diabetes Vasc Dis 2004, 4:401-406.
    • (2004) Br J Diabetes Vasc Dis , vol.4 , pp. 401-406
    • Hermann, L.S.1    Nilsson, B.2    Wettre, S.3
  • 40
    • 35848970300 scopus 로고    scopus 로고
    • Tolerability of prolonged-release metformin (Glucophage(registered trademark) SR) in individuals intolerant to standard metformin - Results from four UK centres
    • Feher MD, Al-Mrayat M, Brake J, Leong KS. Tolerability of prolonged-release metformin (Glucophage(registered trademark) SR) in individuals intolerant to standard metformin - Results from four UK centres. Br J Diabetes Vasc Dis 2007, 7:225-228.
    • (2007) Br J Diabetes Vasc Dis , vol.7 , pp. 225-228
    • Feher, M.D.1    Al-Mrayat, M.2    Brake, J.3    Leong, K.S.4
  • 41
    • 9144241091 scopus 로고    scopus 로고
    • Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital
    • Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004, 181:536-539.
    • (2004) Med J Aust , vol.181 , pp. 536-539
    • Hussein, Z.1    Wentworth, J.M.2    Nankervis, A.J.3    Proietto, J.4    Colman, P.G.5
  • 42
    • 33748784333 scopus 로고    scopus 로고
    • Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus
    • Hung YJ, Kuo SW, Wang CH, Chang HY, Hsieh SH, Landen H. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Invest 2006, 26:559-565.
    • (2006) Clin Drug Invest , vol.26 , pp. 559-565
    • Hung, Y.J.1    Kuo, S.W.2    Wang, C.H.3    Chang, H.Y.4    Hsieh, S.H.5    Landen, H.6
  • 43
    • 36248952778 scopus 로고    scopus 로고
    • Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study
    • 10.1007/s00592-007-0010-y, 17874223
    • Twaites B, Wilton LV, Layton D, Shakir SAW. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2007, 44:233-239. 10.1007/s00592-007-0010-y, 17874223.
    • (2007) Acta Diabetol , vol.44 , pp. 233-239
    • Twaites, B.1    Wilton, L.V.2    Layton, D.3    Shakir, S.A.W.4
  • 44
    • 0033766929 scopus 로고    scopus 로고
    • Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice
    • Hershon KS, Hershon PM. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice. Endocrine Practice 2000, 6:20-25.
    • (2000) Endocrine Practice , vol.6 , pp. 20-25
    • Hershon, K.S.1    Hershon, P.M.2
  • 45
    • 0036808738 scopus 로고    scopus 로고
    • Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents: Median follow-up 29 months
    • Furlong NJ, McNulty SJ, O'Brien SV, Hardy KJ. Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents: Median follow-up 29 months. Pract Diabetes Int 2002, 19:245-249.
    • (2002) Pract Diabetes Int , vol.19 , pp. 245-249
    • Furlong, N.J.1    McNulty, S.J.2    O'Brien, S.V.3    Hardy, K.J.4
  • 46
    • 43449100355 scopus 로고    scopus 로고
    • Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
    • Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008, 10(Suppl 1):25-32.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.SUPPL. 1 , pp. 25-32
    • Alvarez Guisasola, F.1    Tofé Povedano, S.2    Krishnarajah, G.3    Lyu, R.4    Mavros, P.5    Yin, D.6
  • 47
    • 0242332284 scopus 로고    scopus 로고
    • Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study
    • 10.2337/diacare.26.11.2983, 14578227
    • Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26:2983-2989. 10.2337/diacare.26.11.2983, 14578227.
    • (2003) Diabetes Care , vol.26 , pp. 2983-2989
    • Delea, T.E.1    Edelsberg, J.S.2    Hagiwara, M.3    Oster, G.4    Phillips, L.S.5
  • 48
    • 0042425944 scopus 로고    scopus 로고
    • Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions
    • Schatz H, Schoppel K, Lehwalder D, Schandry R. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes 2003, 111:262-266.
    • (2003) Exp Clin Endocrinol Diabetes , vol.111 , pp. 262-266
    • Schatz, H.1    Schoppel, K.2    Lehwalder, D.3    Schandry, R.4
  • 49
    • 4644359214 scopus 로고    scopus 로고
    • Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin
    • 10.1592/phco.24.14.1317.43155, 15628829
    • Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 2004, 24:1317-1322. 10.1592/phco.24.14.1317.43155, 15628829.
    • (2004) Pharmacotherapy , vol.24 , pp. 1317-1322
    • Marceille, J.R.1    Goins, J.A.2    Soni, R.3    Biery, J.C.4    Lee, T.A.5
  • 50
    • 0035998735 scopus 로고    scopus 로고
    • Lipid response to pioglitazone in diabetic patients: Clinical observations from a retrospective chart review
    • 10.1089/15209150260007354, 12079617
    • King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: Clinical observations from a retrospective chart review. Diabetes Technol Ther 2002, 4:145-151. 10.1089/15209150260007354, 12079617.
    • (2002) Diabetes Technol Ther , vol.4 , pp. 145-151
    • King, A.B.1    Armstrong, D.U.2
  • 51
    • 11844290634 scopus 로고    scopus 로고
    • Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting
    • 10.2337/diacare.28.1.20, 15616228
    • Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005, 28:20-26. 10.2337/diacare.28.1.20, 15616228.
    • (2005) Diabetes Care , vol.28 , pp. 20-26
    • Maru, S.1    Koch, G.G.2    Stender, M.3    Clark, D.4    Gibowski, L.5    Petri, H.6    White, A.D.7    Simpson, R.J.8
  • 52
    • 12744255091 scopus 로고    scopus 로고
    • The incidence of congestive heart failure associated with antidiabetic therapies
    • 10.1002/dmrr.480, 15386819
    • Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005, 21:51-57. 10.1002/dmrr.480, 15386819.
    • (2005) Diabetes Metab Res Rev , vol.21 , pp. 51-57
    • Nichols, G.A.1    Koro, C.E.2    Gullion, C.M.3    Ephross, S.A.4    Brown, J.B.5
  • 55
    • 0038618808 scopus 로고    scopus 로고
    • Should we screen diabetic patients using biguanides for megaloblastic anaemia?
    • Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia?. Aust Fam Physician 2003, 32:383-384.
    • (2003) Aust Fam Physician , vol.32 , pp. 383-384
    • Filioussi, K.1    Bonovas, S.2    Katsaros, T.3
  • 56
    • 0042168813 scopus 로고    scopus 로고
    • Polypharmacy and medication adherence in patients with type 2 diabetes
    • 10.2337/diacare.26.5.1408, 12716797
    • Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003, 26:1408-1412. 10.2337/diacare.26.5.1408, 12716797.
    • (2003) Diabetes Care , vol.26 , pp. 1408-1412
    • Grant, R.W.1    Devita, N.G.2    Singer, D.E.3    Meigs, J.B.4
  • 57
    • 21344452562 scopus 로고    scopus 로고
    • Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes
    • 10.1111/j.1572-0241.2005.41690.x, 15929763
    • Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 2005, 100:1317-1321. 10.1111/j.1572-0241.2005.41690.x, 15929763.
    • (2005) Am J Gastroenterol , vol.100 , pp. 1317-1321
    • Chalasani, N.1    Teal, E.2    Hall, S.D.3
  • 58
    • 0031920237 scopus 로고    scopus 로고
    • Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report
    • 10.1136/jamia.1998.0050305, 61304, 9609500
    • Jha AK, Kuperman GJ, Teich JM, Leape L, Shea B, Rittenberg E, Burdick E, Seger DL, Vander Vliet M, Bates DW. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998, 5:305-314. 10.1136/jamia.1998.0050305, 61304, 9609500.
    • (1998) J Am Med Inform Assoc , vol.5 , pp. 305-314
    • Jha, A.K.1    Kuperman, G.J.2    Teich, J.M.3    Leape, L.4    Shea, B.5    Rittenberg, E.6    Burdick, E.7    Seger, D.L.8    Vander Vliet, M.9    Bates, D.W.10
  • 59
    • 2442433545 scopus 로고    scopus 로고
    • Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting
    • Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004, 140:795-801.
    • (2004) Ann Intern Med , vol.140 , pp. 795-801
    • Nebeker, J.R.1    Barach, P.2    Samore, M.H.3
  • 60
    • 49549097900 scopus 로고    scopus 로고
    • Agreement between patient-reported symptoms and their documentation in the medical record
    • 2581509, 18690769
    • Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008, 14:530-539. 2581509, 18690769.
    • (2008) Am J Manag Care , vol.14 , pp. 530-539
    • Pakhomov, S.V.1    Jacobsen, S.J.2    Chute, C.G.3    Roger, V.L.4
  • 61
    • 0035118454 scopus 로고    scopus 로고
    • A computerized method for identifying incidents associated with adverse drug events in outpatients
    • 10.1016/S1386-5056(00)00131-3, 11248601
    • Honigman B, Light P, Pulling RM, Bates DW. A computerized method for identifying incidents associated with adverse drug events in outpatients. Int J Med Inform 2001, 61:21-32. 10.1016/S1386-5056(00)00131-3, 11248601.
    • (2001) Int J Med Inform , vol.61 , pp. 21-32
    • Honigman, B.1    Light, P.2    Pulling, R.M.3    Bates, D.W.4
  • 62
    • 34548058076 scopus 로고    scopus 로고
    • Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance
    • 10.2165/00002018-200730080-00003, 17696579
    • Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007, 30:669-675. 10.2165/00002018-200730080-00003, 17696579.
    • (2007) Drug Saf , vol.30 , pp. 669-675
    • Golomb, B.A.1    McGraw, J.J.2    Evans, M.A.3    Dimsdale, J.E.4
  • 63
    • 4444327078 scopus 로고    scopus 로고
    • How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30
    • 10.1200/JCO.2004.03.025, 15337796
    • Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004, 22:3485-3490. 10.1200/JCO.2004.03.025, 15337796.
    • (2004) J Clin Oncol , vol.22 , pp. 3485-3490
    • Fromme, E.K.1    Eilers, K.M.2    Mori, M.3    Hsieh, Y.C.4    Beer, T.M.5
  • 65
    • 3543114278 scopus 로고    scopus 로고
    • Patients' role in reporting adverse drug reactions
    • 10.1517/14740338.3.4.363, 15268652
    • Van Grootheest K, de Jong-van den Berg LT. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf 2004, 3:363-368. 10.1517/14740338.3.4.363, 15268652.
    • (2004) Expert Opin Drug Saf , vol.3 , pp. 363-368
    • Van Grootheest, K.1    de Jong-van den Berg, L.T.2
  • 66
    • 65249092106 scopus 로고    scopus 로고
    • Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs
    • 10.1002/pds.1708, 19148880
    • Jarernsiripornkul N, Kakaew W, Loalukkana W, Krska J. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf 2009, 18:240-245. 10.1002/pds.1708, 19148880.
    • (2009) Pharmacoepidemiol Drug Saf , vol.18 , pp. 240-245
    • Jarernsiripornkul, N.1    Kakaew, W.2    Loalukkana, W.3    Krska, J.4
  • 67
    • 0023801514 scopus 로고
    • Patients as a direct source of information on adverse drug reactions
    • 10.1136/bmj.297.6653.891, 1834468, 3140967
    • Mitchell AS, Henry DA, Sanson-Fisher R, O'Connell DL. Patients as a direct source of information on adverse drug reactions. BMJ 1988, 297:891-893. 10.1136/bmj.297.6653.891, 1834468, 3140967.
    • (1988) BMJ , vol.297 , pp. 891-893
    • Mitchell, A.S.1    Henry, D.A.2    Sanson-Fisher, R.3    O'Connell, D.L.4
  • 68
    • 67650531870 scopus 로고    scopus 로고
    • Focus on headache as an adverse reaction to drugs
    • 10.1007/s10194-009-0127-1, 19495934
    • Ferrari A, Spaccapelo L, Gallesi D, Sternieri E. Focus on headache as an adverse reaction to drugs. J Headache Pain 2009, 10:235-239. 10.1007/s10194-009-0127-1, 19495934.
    • (2009) J Headache Pain , vol.10 , pp. 235-239
    • Ferrari, A.1    Spaccapelo, L.2    Gallesi, D.3    Sternieri, E.4
  • 69
    • 70349970392 scopus 로고    scopus 로고
    • Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006
    • 10.2165/11316680-000000000-00000, 19810778
    • Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009, 32:1067-1074. 10.2165/11316680-000000000-00000, 19810778.
    • (2009) Drug Saf , vol.32 , pp. 1067-1074
    • Aagaard, L.1    Nielsen, L.H.2    Hansen, E.H.3
  • 70
    • 0036120858 scopus 로고    scopus 로고
    • Patient reporting of potential adverse drug reactions: a methodological study
    • 10.1046/j.0306-5251.2001.01547.x, 1874308, 11874396
    • Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002, 53:318-325. 10.1046/j.0306-5251.2001.01547.x, 1874308, 11874396.
    • (2002) Br J Clin Pharmacol , vol.53 , pp. 318-325
    • Jarernsiripornkul, N.1    Krska, J.2    Capps, P.A.3    Richards, R.M.4    Lee, A.5
  • 71
    • 40949108913 scopus 로고    scopus 로고
    • The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges
    • 10.1002/pds.1533, 18300325
    • Foster JM, van der Molen T, Caeser M, Hannaford P. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol Drug Saf 2008, 17:278-296. 10.1002/pds.1533, 18300325.
    • (2008) Pharmacoepidemiol Drug Saf , vol.17 , pp. 278-296
    • Foster, J.M.1    van der Molen, T.2    Caeser, M.3    Hannaford, P.4
  • 72
    • 33846521254 scopus 로고    scopus 로고
    • Linking laboratory and medication data: new opportunities for pharmacoepidemiological research
    • 10.1515/CCLM.2007.009, 17243908
    • Ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007, 45:13-19. 10.1515/CCLM.2007.009, 17243908.
    • (2007) Clin Chem Lab Med , vol.45 , pp. 13-19
    • Ten Berg, M.J.1    Huisman, A.2    van den Bemt, P.M.3    Schobben, A.F.4    Egberts, A.C.5    van Solinge, W.W.6
  • 73
    • 0035002881 scopus 로고    scopus 로고
    • Using computerized data to identify adverse drug events in outpatients
    • 10.1136/jamia.2001.0080254, 131033, 11320070
    • Honigman B, Lee J, Rothschild J, Light P, Pulling RM, Yu T, Bates DW. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 2001, 8:254-266. 10.1136/jamia.2001.0080254, 131033, 11320070.
    • (2001) J Am Med Inform Assoc , vol.8 , pp. 254-266
    • Honigman, B.1    Lee, J.2    Rothschild, J.3    Light, P.4    Pulling, R.M.5    Yu, T.6    Bates, D.W.7
  • 74
    • 53249132632 scopus 로고    scopus 로고
    • Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    • 10.1038/nrd2664, 18787530
    • Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008, 7:818-826. 10.1038/nrd2664, 18787530.
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 818-826
    • Eichler, H.G.1    Pignatti, F.2    Flamion, B.3    Leufkens, H.4    Breckenridge, A.5
  • 75
    • 0029838837 scopus 로고    scopus 로고
    • Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals
    • 2351951, 8789980
    • Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996, 313:530-531. 2351951, 8789980.
    • (1996) BMJ , vol.313 , pp. 530-531
    • Egberts, T.C.1    Smulders, M.2    de Koning, F.H.3    Meyboom, R.H.4    Leufkens, H.G.5
  • 76
    • 33646140576 scopus 로고    scopus 로고
    • Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE
    • Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group
    • Golder S, McIntosh HM, Duffy S, Glanville J, . Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J 2006, 23:3-12. Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group.
    • (2006) Health Info Libr J , vol.23 , pp. 3-12
    • Golder, S.1    McIntosh, H.M.2    Duffy, S.3    Glanville, J.4
  • 77
    • 4844229862 scopus 로고    scopus 로고
    • Assessing harmful effects in systematic reviews
    • 10.1186/1471-2288-4-19, 497041, 15260887
    • McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Med Res Methodol 2004, 4:19. 10.1186/1471-2288-4-19, 497041, 15260887.
    • (2004) BMC Med Res Methodol , vol.4 , pp. 19
    • McIntosh, H.M.1    Woolacott, N.F.2    Bagnall, A.M.3
  • 78
    • 41749104203 scopus 로고    scopus 로고
    • Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials
    • Donekal S, Shomali ME. Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. Diabetes Res Clin Pract 2008, 80:e4-e6.
    • (2008) Diabetes Res Clin Pract , vol.80
    • Donekal, S.1    Shomali, M.E.2
  • 79
    • 32244433103 scopus 로고    scopus 로고
    • Follow-up of the use of metformin among the high risk population
    • 10.1016/S1130-6343(05)73697-7, 16433568
    • Redondo-Capafons S, Garriga Biosca MR, Pla Poblador R. Follow-up of the use of metformin among the high risk population. Farm Hosp 2005, 29:364-366. 10.1016/S1130-6343(05)73697-7, 16433568.
    • (2005) Farm Hosp , vol.29 , pp. 364-366
    • Redondo-Capafons, S.1    Garriga Biosca, M.R.2    Pla Poblador, R.3
  • 80
    • 2942668406 scopus 로고    scopus 로고
    • Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: A multicenter DUE
    • Burk M, Morreale AP, Cunningham F. Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: A multicenter DUE. Formulary 2004, 39:310-317.
    • (2004) Formulary , vol.39 , pp. 310-317
    • Burk, M.1    Morreale, A.P.2    Cunningham, F.3
  • 81
    • 0037705723 scopus 로고    scopus 로고
    • Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis
    • 10.1592/phco.23.7.861.32727, 12885099
    • Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003, 23:861-865. 10.1592/phco.23.7.861.32727, 12885099.
    • (2003) Pharmacotherapy , vol.23 , pp. 861-865
    • Manley, H.J.1    Allcock, N.M.2
  • 83
    • 0037393015 scopus 로고    scopus 로고
    • Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
    • Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. Am Coll Cardiol 2003, 41:1394-1398.
    • (2003) Am Coll Cardiol , vol.41 , pp. 1394-1398
    • Tang, W.H.1    Francis, G.S.2    Hoogwerf, B.J.3    Young, J.B.4
  • 84
    • 14144253223 scopus 로고    scopus 로고
    • The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office
    • [in German]
    • Fehmann HC. The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office. MMW Fortschr Med 2001, 119(Suppl 2):55-61. [in German].
    • (2001) MMW Fortschr Med , vol.119 , Issue.SUPPL. 2 , pp. 55-61
    • Fehmann, H.C.1
  • 85
    • 3242891451 scopus 로고    scopus 로고
    • Substitution of pioglitazone for troglitazone in patients with type 2 diabetes
    • Kane MP, Busch RS, Bakst G, Hamilton RA. Substitution of pioglitazone for troglitazone in patients with type 2 diabetes. Endocr Pract 2004, 10:18-23.
    • (2004) Endocr Pract , vol.10 , pp. 18-23
    • Kane, M.P.1    Busch, R.S.2    Bakst, G.3    Hamilton, R.A.4
  • 86
    • 33947107876 scopus 로고    scopus 로고
    • Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan
    • 10.1016/j.diabres.2006.08.017, 17109986, on behalf of the PRACTICAL Study Group
    • Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y, . on behalf of the PRACTICAL Study Group Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007, 76:229-235. 10.1016/j.diabres.2006.08.017, 17109986, on behalf of the PRACTICAL Study Group.
    • (2007) Diabetes Res Clin Pract , vol.76 , pp. 229-235
    • Kawamori, R.1    Kadowaki, T.2    Onji, M.3    Seino, Y.4    Akanuma, Y.5
  • 87
    • 0035030824 scopus 로고    scopus 로고
    • Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study
    • 10.1016/S0168-8227(01)00221-2, 11323089
    • Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001, 52:193-204. 10.1016/S0168-8227(01)00221-2, 11323089.
    • (2001) Diabetes Res Clin Pract , vol.52 , pp. 193-204
    • Mertes, G.1
  • 88
    • 34249898882 scopus 로고    scopus 로고
    • Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China
    • Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Invest 2007, 27:397-405.
    • (2007) Clin Drug Invest , vol.27 , pp. 397-405
    • Pan, C.Y.1    Landen, H.2
  • 89
    • 33644848645 scopus 로고    scopus 로고
    • Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes
    • 10.1111/j.1368-5031.2005.00652.x, 16178978
    • Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract 2005, 59:1131-1136. 10.1111/j.1368-5031.2005.00652.x, 16178978.
    • (2005) Int J Clin Pract , vol.59 , pp. 1131-1136
    • Rosak, C.1    Petzoldt, R.2    Wolf, R.3    Reblin, T.4    Dehmel, B.5    Seidel, D.6
  • 90
    • 0034774367 scopus 로고    scopus 로고
    • Efficacy and tolerability of glimepiride in daily practice: A non-interventional observational cohort study
    • Scholz GH, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: A non-interventional observational cohort study. Clin Drug Invest 2001, 21:597-604.
    • (2001) Clin Drug Invest , vol.21 , pp. 597-604
    • Scholz, G.H.1    Schneider, K.2    Knirsch, W.3    Becker, G.4
  • 91
    • 41549132570 scopus 로고    scopus 로고
    • One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study
    • [in French], pour le groupe des investigateurs de l'étude Avantage
    • Slama G, Eschwège E, Bernard MH, Grimaldi A, Oppert JM, Pouchain D, Bégaud B, . pour le groupe des investigateurs de l'étude Avantage One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study. Ann Endocrinol 2008, 69:36-46. [in French], pour le groupe des investigateurs de l'étude Avantage.
    • (2008) Ann Endocrinol , vol.69 , pp. 36-46
    • Slama, G.1    Eschwège, E.2    Bernard, M.H.3    Grimaldi, A.4    Oppert, J.M.5    Pouchain, D.6    Bégaud, B.7
  • 92
    • 24944497145 scopus 로고    scopus 로고
    • Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study
    • Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study. Clin Drug Invest 2005, 25:651-659.
    • (2005) Clin Drug Invest , vol.25 , pp. 651-659
    • Spengler, M.1    Schmitz, H.2    Landen, H.3
  • 93
    • 50649121372 scopus 로고    scopus 로고
    • Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12 772 patients in England
    • 10.2165/00002018-200831100-00003, 18759508
    • Kasliwal R, Wilton LV, Shakir SAW. Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12 772 patients in England. Drug Saf 2008, 31:839-850. 10.2165/00002018-200831100-00003, 18759508.
    • (2008) Drug Saf , vol.31 , pp. 839-850
    • Kasliwal, R.1    Wilton, L.V.2    Shakir, S.A.W.3
  • 94
    • 0035230314 scopus 로고    scopus 로고
    • Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics
    • Kubota K, Kawabe E, Hinotsu S, Hamada C, Ohashi Y, Kurokawa K. Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics. Eur J Clin Pharmacol 2000, 56:831-838.
    • (2000) Eur J Clin Pharmacol , vol.56 , pp. 831-838
    • Kubota, K.1    Kawabe, E.2    Hinotsu, S.3    Hamada, C.4    Ohashi, Y.5    Kurokawa, K.6
  • 95
    • 33646881956 scopus 로고    scopus 로고
    • Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study
    • 10.1007/s00592-006-0203-9, 16710643
    • Marshall V, Wilton L, Shakir SAW. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2006, 43:6-13. 10.1007/s00592-006-0203-9, 16710643.
    • (2006) Acta Diabetol , vol.43 , pp. 6-13
    • Marshall, V.1    Wilton, L.2    Shakir, S.A.W.3
  • 96
    • 45949085098 scopus 로고    scopus 로고
    • A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006
    • 10.1097/MJT.0b013e31817534d5, 18496256
    • Casscells SW, Granger E, Swedorske J, Goldhammer R, Shaheen M, Dorris J, Hong A, Wiktor M. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006. Am J Ther 2008, 15:198-205. 10.1097/MJT.0b013e31817534d5, 18496256.
    • (2008) Am J Ther , vol.15 , pp. 198-205
    • Casscells, S.W.1    Granger, E.2    Swedorske, J.3    Goldhammer, R.4    Shaheen, M.5    Dorris, J.6    Hong, A.7    Wiktor, M.8
  • 97
    • 14844356009 scopus 로고    scopus 로고
    • Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone
    • 10.1111/j.1463-1326.2004.00382.x, 15715889
    • Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005, 7:161-169. 10.1111/j.1463-1326.2004.00382.x, 15715889.
    • (2005) Diabetes Obes Metab , vol.7 , pp. 161-169
    • Rajagopalan, R.1    Iyer, S.2    Perez, A.3
  • 98
    • 0344406225 scopus 로고    scopus 로고
    • Drug-induced renal function impairment: a population-based survey
    • 10.1002/pds.811, 12642977
    • Monster TB, de Jong PE, de Jong-van den Berg LT. Drug-induced renal function impairment: a population-based survey. Pharmacoepidemiol Drug Saf 2003, 12:135-143. 10.1002/pds.811, 12642977.
    • (2003) Pharmacoepidemiol Drug Saf , vol.12 , pp. 135-143
    • Monster, T.B.1    de Jong, P.E.2    de Jong-van den Berg, L.T.3
  • 99
    • 0034332118 scopus 로고    scopus 로고
    • Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus
    • Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract 2000, 6:442-446.
    • (2000) Endocr Pract , vol.6 , pp. 442-446
    • Abbasi, A.A.1    Kasmikha, R.2    Sotingeanu, D.G.3
  • 100
    • 0034232349 scopus 로고    scopus 로고
    • Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control
    • Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract 2000, 6:305-310.
    • (2000) Endocr Pract , vol.6 , pp. 305-310
    • Gavin, L.A.1    Barth, J.2    Arnold, D.3    Shaw, R.4
  • 101
    • 33745036562 scopus 로고    scopus 로고
    • Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes
    • 10.1007/BF02850136, 16751163
    • Taki H, Maki T, Iso T, Iwamoto K, Kajiura T. Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes. Adv Ther 2006, 23:307-324. 10.1007/BF02850136, 16751163.
    • (2006) Adv Ther , vol.23 , pp. 307-324
    • Taki, H.1    Maki, T.2    Iso, T.3    Iwamoto, K.4    Kajiura, T.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.